RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome. — CFSMEATLAS
RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome.
Tiev, Kiet Phong, Demettre, Edith, Ercolano, Philippe et al. · Clinical and diagnostic laboratory immunology · 2003 · DOI
Quick Summary
This study looked at a protein called RNase L in the immune cells of ME/CFS patients and healthy people. Researchers found that ME/CFS patients had a different pattern of RNase L forms compared to healthy volunteers, and this pattern could potentially be used as a simple blood test to help diagnose ME/CFS. The test showed promise in distinguishing ME/CFS patients from healthy people in this small group.
Why It Matters
ME/CFS currently lacks objective diagnostic markers, making diagnosis difficult and often delayed. If validated, the RNase L isoform ratio could become a simple blood test to help clinicians objectively diagnose ME/CFS and potentially guide treatment decisions. This study provides early evidence that a measurable immune abnormality may underlie ME/CFS pathology.
Observed Findings
ME/CFS patients had significantly elevated RNase L 37 kDa/83 kDa ratios compared to healthy controls.
A threshold ratio of 0.4 yielded 91% sensitivity and 71% specificity for distinguishing ME/CFS patients.
Positive predictive value was 71% and negative predictive value was 91% using this threshold.
The RNase L ratio abnormality was observed in the absence of acute infection or chronic inflammation in tested subjects.
Both men and women with ME/CFS showed this pattern, with mean age around 43 years.
Inferred Conclusions
The RNase L isoform ratio may serve as a potential biochemical marker for ME/CFS diagnosis.
Elevated RNase L ratios could help distinguish ME/CFS patients from healthy individuals.
The RNase L abnormality may reflect an underlying immunological dysfunction in ME/CFS.
Larger prospective and follow-up studies are needed to confirm the stability and clinical utility of this biomarker.
Remaining Questions
Is the RNase L ratio stable over time in individual ME/CFS patients, or does it fluctuate with disease activity?
What This Study Does Not Prove
This small study does not prove that RNase L ratio abnormalities cause ME/CFS—only that they are associated with the condition. The findings have not been confirmed in larger populations, and it is unclear whether this biomarker is stable over time or how it changes with disease progression or treatment. The study cannot establish whether this ratio would be useful for monitoring disease activity or predicting outcomes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →